Company overview
ReiThera is an Italian CDMO specializing in process development and GMP manufacturing of viral vectors including AAV, Ad (GRAd platform), MVA, HSV, and LVV for gene therapies and vaccines. The company operates a state-of-the-art facility in Rome with bioreactors up to 2000-3000L scale, fixed-bed systems, fill/finish suites, and quality control labs, supporting end-to-end services from vector design to commercial production. Key platforms include ReiCell-AAV for scalable AAV production and validated MVA processes.
Reithera is listed in the NovaPharmaNews Supplier Hub as a CDMO & Manufacturing partner serving United States & Americas. Core focus areas include viral vector cdmo, aav manufacturing, gene therapy cdmo, mva vectors, gmp viral production.
Industry categories: CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Reithera include Cdmo — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://reithera.com
- Categories
- CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- viral vector cdmo, aav manufacturing, gene therapy cdmo, mva vectors, gmp viral production
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What viral vectors does ReiThera manufacture?
- ReiThera specializes in AAV, adenoviral vectors (GRAd platform), MVA, HSV, and lentiviral vectors (LVV) for gene therapies and vaccines.
- What are ReiThera's manufacturing capabilities and scales?
- The Rome facility features bioreactors from 2L to 2000-3000L, fixed-bed systems, four independent GMP suites, fill/finish, and QC labs for clinical and commercial production.
- Does ReiThera support full development to commercialization?
- Yes, ReiThera provides end-to-end CDMO services from vector design and process development through GMP manufacturing and immunomonitoring for gene therapy and vaccine programs.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
